Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term comparison of intranasal esketamine versus extended-release quetiapine added to SSRI/SNRI in treatment-resistant major depressive disorder
MOH_2020-08-31_009097Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in major depressive disorder (MDD) comparing Esketamine + SSRI/SNRI with Quetiapine extended release + SSRI/SNRI (2 arms). Started Aug 2020; status: completed.
02
Drugs
esketaminequetiapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on MOH_2020-08-31_009097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-08-31_009097.